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Association of asymmetric dimethylarginine with
sickle cell disease-related pulmonary hypertension
Pulmonary hypertension (PHT) occurs in approximate-
ly 30% of adult sickle cell patients and is associated with
a high risk of early death. Hemolysis driven reductions in
nitric oxide (NO) bioavailability resulting from NO scav-
enging by cell free hemoglobin and increased arginase
activity are of importance in the pathophysiology of SCD
related PHT.1
Elevated plasma concentrations of asymmetric
dimethylarginine (ADMA) contribute to limiting NO
bioavailability in SCD.2 ADMA and symmetric dimethy-
larginine (SDMA) derive from the irreversible post-trans-
lational methylation of arginine residues by protein argi-
nine methyltransferases (PRMT) and are released as free
amino acids upon proteolysis. ADMA (but not SDMA)
competitively inhibits NO synthase (NOS) enzymes,
thereby limiting NO production. ADMA is degraded by
dimethylarginine dimethylaminohydrolases (DDAH)
whereas SDMA is mainly cleared renally.3 Elevated plas-
ma ADMA concentrations occur in several forms of PHT
and are associated to PHT outcome.4,5 We investigated
whether ADMA concentrations are associated with PHT
in SCD. 
Serum and EDTA plasma samples were available from
adult sickle cell patients consecutively screened for PHT
with echocardiography as previously reported.6 Mild and
moderate-severe PHT are defined as tricuspid regurgitant
jet flow velocity (TRV) of 2.5-2.9 m/s and TRV≥3 m/s
respectively, with pulmonary-artery pressures considered
normal in patients with trace or no tricuspid regurgita-
tion (with TRV assigned 1.3 m/s).1 Plasma concentrations
of ADMA, SDMA, amino acids and serum soluble vascu-
lar cell adhesion molecule-1 (sVCAM-1) levels were
determined as previously described.2,7 For analysis, HbSS
and HbSβ0-thalassemia patients were grouped together,
as were HbSβ+-thalassemia and HbSC patients. p-values
<0.05 were considered statistically significant (SPSS
12.0.2, SPSS Inc, Chicago, IL, USA). The study was carried
out in accordance with the principles of the Declaration
of Helsinki.
Two out of 19 PHT patients had moderate-severe PHT.
Hydroxyurea use did not differ between patients with
and without PHT and no patients used anticoagulation,
calcium antagonists, endothelin receptor blockers or
sildenafil. Between group comparisons were only per-
Table 1. Demographics and laboratory parameters in sickle cell
patients with and without pulmonary hypertension. 
HbSS (n=40)/ HbSC (n=16) / 
HbSβ0-thalassemia (n=6) HbSβ+-thalassemia (n=5) 
PHT– PHT+ p PHT– PHT+
N 28 18 20 1
Age (years) 33 (21-44) 28 (22-52) 0.80 29 (23-39) 41
Male:female 6:22 5:13 10:10 0:1
TRV (m/s) 2.0 (1.3-2.3) 2.7 (2.6-2.8) 2.1 (1.3-2.2) 2.6
sPAP*(mmHg) 21 (12-28) 34 (32-43) 21 (12-25) 31
Hb (mmol/L) 5.7 (5.0-6.2) 4.9 (4.2-5.9) 0.05 7.0 (6.6-7.6) 6.5
HbF (%) 10.6 5.9 0.13 1.0 4
(6.1-18.3) (2.2-14.1) (1.0-2.4)
LDH (U/L) 369 575 0.02 231 261
(300-515) (388-846) (202-359)
GFR (mL/min)** 151 120 0.10 140 114
(120-195) (66-172) (125-160)
ADMA (µmol/L) 0.57 0.63 0.01 0.50 0.48
(0.52-0.65) (0.58-0.79) (0.45-0.58)
SDMA (µmol/L) 0.47 0.51 0.07 0.46 0.47
(0.42-0.55) (0.47-0.83) (0.44-0.56)
Arginine (µmol/L) 45 46 0.26 67 56
(32-56) (41-62) (57-79)
Ornithine (mmol/L) 56 56 0.41 56 44
(42-66) (45-75) (49-62)
Citrulline (mmol/L) 23 27 0.66 29 32
(16-32) (20-32) (24-33)
Proline (mmol/L) 208 209 0.84 197 257
(162-257) (176-234) (148-247)
Arginine/ornithine 0.84 0.93 0.45 1.14 1.1
(0.66-1.0) (0.72-1.15) (0.86-1.21)
Arginine/citrulline 1.87 1.98 0.84 2.1 1.5
(1.66-2.49) (1.43-2.65) (1.6-2.3)
Arginine/proline 0.23 0.25 0.41 0.30 0.19
(0.18-0.31) (0.19-0.35) (0.21-0.37)
sVCAM-1 (ng/mL) 1089 1542 0.007 851 971
(801-1239) (1119-1880) (628-1011)
Data are presented as medians with their corresponding inter quartile range.
A p-value <0.05 is considered statistically significant. *Right ventricular systolic
pressure was estimated based on the modified Bernoulli equation (1) and
considered to be equal to the systolic pulmonary artery pressure (sPAP) in
absence of right ventricular outflow obstruction. **Glomerular filtration (GFR)
rate calculated with Cockcroft and Gault-formula (males: creatinine clearance=
1.23xweight x (140-age)/serum creatinine, females: creatinine clearance =
1.03xweight x (140-age)/serum creatinine). 
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formed in HbSS/HbSβ°-thalassemia patients as only 3
HbSC/HbSβ+-thalassemia patients had PHT of whom one
had blood samples drawn. 
ADMA concentrations in patients without PHT were
high compared to previously reported values in healthy
race-matched controls. Irrespective of PHT, HbSS/HbSβ°-
thalassemia patients were characterized by lower hemo-
globin, higher LDH, ADMA and sVCAM-1 concentra-
tions than HbSC/HbSβ+-thalassemia patients (all
p<0.001). ADMA and sVCAM-1 were higher in
HbSS/HbSβ°-thalassemia patients with PHT than those
without PHT, with a significant correlation between
ADMA and TRV as well (see correlation studies in Online
Supplementary Table 2). sVCAM-1 and hemoglobin were
significantly correlated to TRV in HbSS/HbSβ0-tha-
lassemia patients (rs=0.49, p=0.002, rs=-0.30, p=0.04,
respectively). SDMA, but not ADMA, was significantly
correlated to GFR (rs=-0.66, p<0.001, rs=-0.08, p=0.60,
respectively) in HbSS/HbSβ°-thalassemia patients. Given
the relation between hemolysis and methylarginine con-
centrations, it is likely that the hemolytic rate is an
important determinant of their production in SCD (likely
due to the increased protein turn-over in the stress ery-
thropoiesis), also explaining the higher concentrations in
HbSS/HbSβ0-thalassemia patients. A relative decrease in
renal function (generally more evident in HbSS/HbSβ0-
thalassemia patients) could contribute especially to
SDMA elevations. Contributing factors related to the
pulmonary vasculature could be shear stress induced
PRMT activity8 and hypoxia induced DDAH downregu-
lation.9 Although difference in ADMA between patients
with and without PHT seems modest, even small
increases in extra-cellular ADMA lead to significant
intra-cellular NOS inhibition through preferred cellular
ADMA uptake over arginine.3 Indeed, plasma ADMA
concentrations ≥0.64µmol/L are associated with strongly
reduced pulmonary artery endothelial NOS expression
and early death in PHT patients.5 Based upon the strong
correlation of sVCAM-1 to ADMA, it would be interest-
ing to hypothesize that chronic hemolysis induced
ADMA elevations significantly contribute to endothelial
activation and dysfunction in SCD via NOS inhibition,
and that patients with higher ADMA concentrations are
more prone to develop a vasculopathy leading to compli-
cations such as PHT over time.
Arginase activity (reflected by arginine to ornithine
ratios) is elevated in sickle cell patients with moderate-
severe PHT but, in agreement with previous studies,1,10
did not differ between patients with mostly mild PHT
and those without PHT. Conceding the fact that we did
not determine plasma arginase activity directly, these
data suggest that ADMA could play a role of pathophys-
iological importance at a relatively earlier stage than
arginase activity. 
The relatively small number of patients needs to be
taken into account when interpreting these data and no
conclusions can be drawn about HbSC/HbSβ+-tha-
lassemia patients. Also, right heart catheterization
remains the gold standard diagnostic test for PHT and is
recommended in sickle cell patients with moderate-
severe PHT detected with echocardiography. However,
given the excellent correlation between pulmonary
artery pressure and TRV in SCD,1 and the fact that an ele-
vated TRV is the result of solely left-sided heart disease
in only a minority of cases,11 the lack of right heart
catheterization is unlikely to have significantly affected
our results. Lastly, our data are largely limited to patients
with mild PHT. Nonetheless, mortality is high in these
patients1 and plasma ADMA concentrations were well in
the range associated with death in other forms of PHT.4,5
Taken together, our data identify an association of
plasma ADMA concentrations to PHT in SCD, possibly
identifying a novel factor of importance in its pathophys-
iology. Also, ADMA induced limitation of NO produc-
tion may well provide an important new mechanistic link
between hemolysis and the characteristic endothelial
activation of SCD. 
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Effect of JAK2 V617F on thrombotic risk in
patients with essential thrombocythemia:
measuring the uncertain
Current data about thrombotic risk in ET patients har-
boring the JAK2 V617F mutation remain partially incon-
clusive.1,2 A systematic literature review of MEDLINE up
to February 2008 to identify studies of ET in the JAK2 era
was conducted using the following search algorithm:
JAK2 AND (essential OR thrombocytosis OR thrombo-
cythemia OR thrombosis). All searches were limited to
studies of humans published in English. A manual search
of abstracts was initially conducted and relevant studies
were retrieved in full text. In addition, a manual review
of references was carried out to identify any additional
relevant articles. To be included in the analysis, studies
had to report the prevalence of thrombosis in JAK2
V617F patients and in wild-type carriers with ET. 
Weighted averages were reported as Odds Ratios (ORs)
along with their 95% Confidence Intervals (95%CIs) to
quantify the effect of JAK2 positivity on the thrombotic
risk in each study. Major thrombotic events were extract-
ed, including strokes and transient ischemic attacks,
myocardial infarctions and angina pectoris, peripheral
artery occlusion, deep vein thrombosis and pulmonary
embolism. 
Pooled ORs were calculated according to the Mantel-
Haenszel method for fixed effects (FE) and DerSimonian-
Laird for random effects (RE). Statistical heterogeneity
was measured using the χ2 Q test (p<0.10 is considered
representative of significant statistical heterogeneity) and
the I2 statistic, as previously described.3 To establish the
effect of clinical heterogeneity between studies, subgroup
analysis was performed. Although the selection of a ran-
dom- vs. fixed-effects model remains controversial, a
fixed-effects model appears more appropriate whenever
heterogeneity is limited.
A total of 492 relevant studies were initially retrieved.
Among them, 17 studies (see Online Supplementary
Appendix) met the inclusion criteria. Incidence figures for
thrombosis vary from 17% to 43%, and JAK2 V617F pos-
itivity varies from 37% to 71%. A significant association
of JAK2 mutation with thrombosis was evident in half of
these studies whereas no such correlation was docu-
mented in the remaining studies (Table 1A).
Meta-analysis of 2,905 patients with ET and 778
patients with thrombosis (Table 1B), showed JAK2 V617F
patients have a two-fold risk of developing thrombosis
(ORRE 1.84, 95%CI 1.40-2.43) with significant hetero-
geneity between studies (I2=42.5%). 
The statistical heterogeneity reported should be con-
sidered a reflection of clinical heterogeneity between dif-
ferent study populations, type (prospective vs. retrospec-
tive) and variability in follow-up. Moreover, JAK2 V617F
patients are older at diagnosis, have higher hemoglobin
levels, higher leukocyte counts and lower platelet
counts.2,4-6 Leukocytosis is regarded as an additional fac-
tor for thrombosis whereas thrombocytosis is not,5,6 and
additional evidence is provided to support the role of
granulocytes in MPD-associated thrombosis.7 The above
observations are consistent with the superior effective-
ness of hydroxyurea (a non-specific myelosuppressive
agent) compared to anagrelide (a platelet-specific cytore-
ductive agent) in high risk ET8,9 and supported by the lack
of an increased risk of thrombosis associated with
extreme thrombocytosis in otherwise low-risk ET.10 Age
is a well-established confounder in thrombotic risk, and
cardiovascular risk factors may vary between study
groups. However, 2 recent studies have demonstrated
that the presence of cardiovascular risk factors does not
modify thrombotic risk in patients with ET who experi-
ence first-time thrombosis.11,12 In fact, recurrent thrombo-
sis is again predicted by age (>60 years) and thrombosis
history12 factors with well-established prothrombotic
effect in ET.6,11
Finally, the allele burden of the mutated JAK2 gene, the
effect of which cannot be estimated, may account for the
diversity between studies. Results so far remain contra-
dictory.2,13
Given the exaggerating effect of smaller studies, larger
Table 1A. Characteristics of studies included in the analysis. 
Study Type N JAK2 V617F Thrombosis Association of
JAK2 V617F
with thrombosis
Baxter EJ, 2005 P 51 29 (56.9) 12 (23.5%) No
Campbell PJ, 2005 P 776 414 (53.3%) 137 (17.7%) Yes
Wolanskyj AP, 2005 R 150 73 (48.7%) 62 (41.3%) No
Cheung B, 2006 R 60 29 (48%) 26 (43%) Yes
Heller PG, 2006 R 50 24 (48%) 12 (24.0%) Yes
Stevenson WS, 2006 R 27 10 (37%) 7 (25.9%) No
Alvarez-Larran A, 2007 P 103 44 (42.7%) 22 (21.4%) No
Finnazzi G, 2007 R 179 103 (57.5%) 47 (26.3%) Yes
Hsiao HH, 2007 R 53 35 (66%) 17 (32.1%) Yes
Kittur J, 2007 R 176 96 (54.5) 70 (39.8%) No
Ohyashiki K, 2007 R 49 31 (63.3%) 11 (22.5%) Yes
Pemmaraju N, 2007 P 80 38 (47%) 26 (32.5%) No
Rudzki Z, 2007 R 59 38 (64.4%) 24 (40.7%) No
Speletas M, 2007 P 111 77 (69.3%) 45 (40.5%) No
Toyama K, 2007 P 82 58 (70.7%) 16 (19.5%) Yes
Vannucchi AM, 2007 R 639 382 (59.8%) 188 (29.4%) Yes
Antonioli E, 2008 R 260 165 (63.5%) 56 (21%) No
The squares and lines show the estimated odds ratios and their 95% CIs. The size
of each square is proportional to the amount of information (weight) available in
the subgroup. Overall estimates are shown by a diamond, with the width
representing the 95% CI.
